🇺🇸 gonadotropin releasing hormone-agonist in United States

15 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Budd-Chiari Syndrome — 2 reports (13.33%)
  2. Decreased Appetite — 2 reports (13.33%)
  3. Oedema Peripheral — 2 reports (13.33%)
  4. Off Label Use — 2 reports (13.33%)
  5. Ovarian Hyperstimulation Syndrome — 2 reports (13.33%)
  6. Abdominal Distension — 1 report (6.67%)
  7. Abdominal Pain — 1 report (6.67%)
  8. Ascites — 1 report (6.67%)
  9. Blindness Unilateral — 1 report (6.67%)
  10. Blood Pressure Increased — 1 report (6.67%)

Source database →

gonadotropin releasing hormone-agonist in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is gonadotropin releasing hormone-agonist approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for gonadotropin releasing hormone-agonist in United States?

Alexandria University is the originator. The local marketing authorisation holder may differ — check the official source linked above.